Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
SCYX
#3582
SCYNEXIS, Inc.
0.7
5
+4.17%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+4.17%
Monthly Change
-6.25%
6 month change
-9.64%
Year Change
-25.00%
Previous Close
0.7
2
Open
0.7
5
Bid
Ask
Low
0.7
5
High
0.7
5
Volume
3
Markets
US Stock Market
Healthcare
SCYX
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
20.62 M
28.94 M
33.32 M
37.75 M
38.98 M
—
Valuation ratios
Enterprise value
64.76 M
72.05 M
2.17 M
49.39 M
31.12 M
96.11 M
Price to earnings ratio
—
—
-0.98
1.59
-2.75
-7.65
Price to sales ratio
—
—
12.05
0.76
15.67
56.4
Price to cash flow ratio
—
—
0.77
1.78
2.44
6.64
Price to book ratio
—
—
18.98
1.47
1.07
1.63
Enterprise value to EBITDA ratio
—
—
—
1.08
-0.85
—
Profitability ratios
Return on assets %
0.54
0.27
0.72
0.52
0.23
0.4
Return on equity %
2.42
0.8
19.42
0.92
0.39
0.56
Return on invested capital %
1 449.27
1 370.11
2 519.68
1 356.87
474.32
1 077.13
Gross margin %
—
100
100
79.18
100
400
Operating margin %
—
462.19
1 684.48
51.85
990.84
7 391.77
EBITDA margin %
—
—
—
32.5
-980.54
—
Net margin %
—
249.68
1 233.55
47.84
568.29
5 544.19
Liquidity ratios
Quick ratio
—
8
4.44
6.26
—
—
Current ratio
3.72
8.03
4.49
6.26
3
19.78
Inventory turnover
—
—
—
64.91
—
—
Asset turnover
0
0.12
0.05
1.3
0.03
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
0.24
0.39
0
—
—
Long term debt to total equity ratio
—
0.7
10.64
0
—
—
Per share metrics
Operating cash flow per share
—
—
1.87
1.24
0.49
0.68
EBIT per share
—
—
—
0.9
-0.77
—
EBITDA per share
—
—
—
0.94
-0.76
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
1.72
2.03
1.55
4.33
Net current asset value per share
—
—
1.86
2.11
1.49
4.66
Tangible book value per share
—
—
0.07
1.51
1.14
3.78
Working capital per share
—
—
1.44
1.77
0.99
3.59
Book value per share
—
—
0.08
1.51
1.14
3.78
News
SCYNEXIS doses first patients in SCY-247 IV formulation trial
JERSEY CITY - FDA grants fast track and QIDP designations to SCYNEXIS drug
Scynexis receives 180-day extension from Nasdaq to meet listing requirements
SCYNEXIS receives $7 million annual grant for antifungal research
Guggenheim lowers SCYNEXIS stock price target to $3 after GSK trial resolution
SCYNEXIS receives $22 million from GSK as MARIO study ends
Scynexis to receive $24.3 million from GSK as MARIO study ends per new agreement
SCYNEXIS reports positive Phase 1 results for antifungal drug SCY-247
Scynexis Inc earnings beat by $0.06, revenue topped estimates
SCYNEXIS resumes Phase 3 antifungal study after FDA lift
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update